Board of Directors

After the general meeting, the board of directors is the Company’s highest decision-making body. The board of directors shall be responsible for the organization and management of the Company’s affairs, for example by establishing targets and strategies, securing procedures and systems for monitoring of set targets, continuously assess the Company’s financial position and evaluate the operational management.

Per Wold-Olsen, Chairman of the Board

Per Wold-Olsen, MBA

Chairman

Per Wold-Olsen was appointed as Chairman of the Board in 2018.

 

Per has an extensive experience in the pharmaceutical industry and has held many different positions within Merck & Co Inc. He served on Merck’s management team between 1994-2006. Since 2006 he has served on several boards including Lundbeck, Pharmaset and Royal Dutch Numico.

 

Per holds a MBA in Economics and Administration from Handelshøyskolen BI and a MBA in Management and Marketing from the University of Wisconsin.

 

Born: 1947

Board Committees: Chairman of the Remuneration Committee and member of the Audit and Nomination Committee

Holdings in Oncopeptides: 88,845 shares and 32,845 Share Awards**

Other current positions: Chairman of the Board of MMV (Medicines for Malaria Venture) and GN Store Nord A/S. He is also a Board member of Gilead Sciences, Inc.

 

Independent in relation to the Company and its management and in relation to major shareholders.

Brian Stuglik - Board member

Brian Stuglik, B.Pharm

Board member

Brian Stuglik was appointed to the Board of Oncopeptides 2018.

 

Brian has a long and broad experience from the pharmaceutical industry. He has spent 30 years in different positions within Eli Lilly, including American as well as global roles and responsibilities. Over the past 25 years, his work has been focused on product strategy and commercialization for oncology products.

 

Brian holds a Bachelor of Pharmacy from Purdue University, US.

 

Born: 1959

Board Committees: Member of the Remuneration Committee

Holdings in Oncopeptides: 13,142 Share Awards**

Other current positions: CEO of Verastem Inc. Founder of, and since 2016 runs, Proventus Health Solutions LLC. Member of the American Society of Clinical Oncology, the American Association for Cancer Research and the International Association for Lung Cancer Studies.

 

Independent in relation to the Company and its management and in relation to major shareholders.

Cecilia Daun Wennborg - Board member

Cecilia Daun Wennborg, MSc

Board member

Cecilia Daun Wennborg was appointed to the board of Oncopeptides in 2017.

 

Cecilia has 14 years of experience from board positions in listed companies and 20 years of experience from operational positions in the insurance, bank, care and healthcare sectors, inter alia as CFO and CEO of Skandia Link, Head of Skandia Sverige, CFO of Carema Vård & Omsorg AB and Ambea AB, CEO of Carema Vård & Omsorg AB and deputy CEO of Ambea AB.

 

Cecilia holds a MSc in Business and Economics from Stockholm University.

 

Born: 1963

Board Committees: Chairman of the Audit Committee

Holdings in Oncopeptides: 11,800 shares and 13,142 Share Awards**

Other current assignments: Board Member in Getinge AB, Bravida Holding AB, ICA Gruppen AB, Loomis AB, Atvexa AB, Insamlingsstiftelsen Oxfam Sverige, Hoist Finance AB, Hotel Diplomat AB and CDW Konsult AB. Member of the Swedish Securities Council.

 

Independent in relation to the Company and its management and in relation to major shareholders.

Jarl Ulf Jungnelius

Jarl Ulf Jungnelius, MD, PhD

Board member

Jarl Ulf Jungnelius was appointed to the board of Oncopeptides in 2011.

 

Ulf is a licensed medical practitioner and a specialist in several areas, including oncology. He has published several scientific articles and has more than 25 years of experience from leadership positions in both large academic and corporate institutions.

 

He has been instrumental in the development and registration of gemcitabine (Gemzar), premetrexed (Alimta), Sunitinib (Sutent), lenalidomide (Revlimid) and the albumin bound nanoparticle paclitaxel (Abraxane).

 

Born: 1951
Holdings in Oncopeptides: 57,750 shares and 13,142 Share Awards**
Other current positions: CEO of Isofol Medical AB. Senior Oncology Advisor for Noxxon AG. Board Member of Biovica International AB, Ryvu Therapeutics and HealthCom GmbH.

 

Independent in relation to the Company and its management and in relation to major shareholders.

Jennifer Jackson

Jennifer Jackson, PhD

Board member

Jennifer Jackson was appointed to the board of Oncopeptides in 2018.

 

Jennifer is Senior Vice President of Regulatory Affairs and Quality Assurance and a member of the executive leadership team at Tesaro. She has more than twenty-five years of experience in global clinical development and market registration of small molecules and biologics across multiple therapeutic areas including oncology. 

 

Jennifer has had several senior roles at Cubist Pharmaceuticals, Biogen, Vertex och Bristol-Myers Squibb.

 

Jennifer earned her Ph.D. in Genetics at Cornell University and did her postdoctoral work at Massachusetts Institute of Technology. She is a member of the American Society of Clinical Oncology.

 

Born: 1953
Holdings in Oncopeptides: 15,312 Share Awards**
Other current positions: Senior Vice President of Regulatory Affairs and Quality Assurance and a member of the executive leadership team at Tesaro.

 

Independent in relation to the Company and its management and in relation to major shareholders.

Per Samuelsson

Per Samuelsson, MSc

Board member

Per Samuelsson was appointed to the board of Oncopeptides in 2012.

 

Per is a partner at HealthCap, a life sciences venture capital business.

 

Per has over 15 years investment banking experience, mainly with Aros Securities based in Sweden. At Aros Securities he held several roles including being a Director in the corporate finance department where he specialized in merger transactions, initial public offerings and equity incentive programs. Per also held the role of Head of Research at Aros Securities.

 

Per holds an MSc in Engineering from the Institute of Technology in Linköping, Sweden.

 

Born: 1961
Board Committees: Member of the Audit Committee and the Remuneration Committee
Holdings in Oncopeptides: -
Other current positions: Board Member of Ancilla AB, Cantando AB, Cantando Holding AB, HealthCap AB, HealthCap Annex Fund I-II GP AB, HealthCap Orx Holdings GP AB, HealthCap 1999 GP AB, HealthCap III Sidefund GP AB, Skipjack AB, SwedenBIO Service AB, Nordic Nanovector ASA and Targovax ASA.

 

Independent in relation to the Company and its senior management, but not in relation to major shareholders. Partner in HealthCap and holder of directorships in several companies within the HealthCap Group.

* Each employee option entitles the holder to acquire 900 shares per option in the company.
** One share award entitles to one share in accordance with existing terms. For more information and terms please read under Corporate Governance – Remuneration.

Holdings in Oncopeptides AB (publ) as of September 2, 2021.